论文部分内容阅读
[目的]比较XELOX方案(奥沙利铂联合卡培他滨)与SP方案(替吉奥联合顺铂)治疗晚期胃癌的疗效及安全性。[方法]对36例晚期胃癌患者采用XELOX方案治疗,与SP方案(37例)进行疗效比较。[结果]XELOX方案组总有效率为47.2%(17/36),SP方案组总有效率为51.4%(19/37),两组间比较差异无统计学意义(P>0.05);两组中位疾病进展时间和中位生存时间比较无差异(P>0.05)。XELOX组手足综合征、神经毒性发生率较SP组高,但骨髓抑制发生率较SP组低,两组比较差异有统计学意义(P<0.05)。[结论]XELOX方案和SP方案对晚期胃癌的疗效相近,不良反应可耐受,临床中可根据患者年龄、一般状况及其他预后因素个体化选择化疗方案。
[Objective] To compare the efficacy and safety of XELOX regimen (oxaliplatin combined with capecitabine) and SP regimen (tigenex combined with cisplatin) in the treatment of advanced gastric cancer. [Method] Thirty-six patients with advanced gastric cancer were treated with XELOX regimen and compared with SP regimen (37 cases). [Results] The total effective rate was 47.2% (17/36) in the XELOX group and 51.4% (19/37) in the SP group. There was no significant difference between the two groups (P> 0.05) Median disease progression time and median survival time no difference (P> 0.05). The incidence of hand-foot syndrome and neurotoxicity in XELOX group was higher than that in SP group, but the incidence of bone marrow suppression was lower than that in SP group. There was significant difference between the two groups (P <0.05). [Conclusion] The efficacy of XELOX regimen and SP regimen is similar to that of advanced gastric cancer, and adverse reactions are tolerable. Chemotherapy regimens can be individualized according to patient’s age, general condition and other prognostic factors in clinical practice.